Recent Company News

• 05:06 AM ET Feb 04, 2026
  

  Shanghai Pharmaceuticals lists 30% stake in Sino-American Shanghai Squibb Pharmaceuticals for sale at reserve price of CNY1.02B (HK$11.75, 0.00)

• 11:39 PM ET Feb 02, 2026
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (122 total)

• 10:56 PM ET Feb 02, 2026
  

  StreetAccount Summary: China Stocks reaching new 52-week highs/lows (14 total)

• 10:38 PM ET Feb 01, 2026
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (98 total)

• 03:07 AM ET Jan 29, 2026
  

  NMPA approves Shanghai Pharmaceuticals' Qiling powder for treatment of complications arising from gout (HK$11.97, 0.00)

• 10:54 PM ET Jan 21, 2026
  

  StreetAccount Summary: China Stocks reaching new 52-week highs/lows (36 total)

• 03:14 AM ET Jan 20, 2026
  

  Shanghai Pharmaceuticals Holding obtains NMPA clinical trial approval for B023 cell injection (HK$11.91, 0.00)

• 10:48 PM ET Jan 18, 2026
  

  StreetAccount Summary: China Stocks reaching new 52-week highs/lows (28 total)

• 10:33 PM ET Jan 18, 2026
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (144 total)

• 03:42 AM ET Jan 09, 2026
  

  Shanghai Pharmaceuticals Holding obtains NMPA drug registration certificate for pyridostigmine oral solution in myasthenia gravis